BDBM444532 US10662186, Compound 52::US10988476, Compound I-52

SMILES CN(C)CCN1CCc2nc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C5CC5)c4c3)ccc2C1

InChI Key InChIKey=UZUCFTPPULEGQO-UHFFFAOYSA-N

Data  17 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 444532   

TargetCyclin-dependent kinase 7(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 223nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 332nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 223nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 91.5nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 368nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 700nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 3.81nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 3.88nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 332nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK4 (1 to 303 residues)/cyclin D3 (1 to 292 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 5(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 91.5nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 368nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 700nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 3.81nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 3.88nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK6 (1 to 326 residues)/cyclin D3 (1 to 292 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444532(US10662186, Compound 52 | US10988476, Compound I-5...)
Affinity DataIC50: 145nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK2 (1 to 298 residues)/cyclin A2 (1 to 432 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed